HER2 has long been known to be amplified and overexpressed in breast [66], gastric [67], and bladder cancers [68] and large scale copy number analysis confirms that HER2 is amplified most frequently in gastric followed by breast cancer (Figure 3A). This evidence concerns the gene ERBB2 and urinary bladder carcinoma.